You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,005,299


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,005,299
Title:Expression of heterologous genes according to a targeted expression profile
Abstract: A gene trap vector comprises a DNA construct containing an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence; this expression unit is used in gene trap protocols to obtain expression of the heterologous gene in the host.
Inventor(s): Smith; Austin Gerard (Edinburgh, GB), Mountford; Peter Scott (Elsderwick, AU), Lathe; Richard Frank (Edinburg, GB)
Assignee: The University of Edinburgh (GB)
Application Number:09/348,469
Patent Claims:1. A method of inserting a gene of interest into an endogenous gene in a mouse embryonic stem cell such that the gene of interest is expressed in said mouse embryonic stem cell, wherein said method comprises transforming the mouse embryonic stem cell with a gene trap vector comprising a heterologous gene coding sequence: 5' X-A-P-B-Q-C-Y-3' wherein: X and Y are substantially homologous with separate sequences of the endogenous gene, and are of sufficient length to undergo homologous recombination with the endogenous gene so as to insert the A-P-B-Q-C elements into the host cell's genome; P is an internal ribosome entry site (IRES); Q is the gene of interest; A, B, and C are each independently at least one of a linker sequence and a covalent bond; a polyadenylation site is located 3' (downstream) of Q; a splice acceptor site is located 5' (upstream) of P; and wherein the heterologous gene coding sequence lacks a promoter element.

2. The method of claim 1 where the heterologous gene coding sequence is randomly inserted into an endogenous gene so that transcription of the heterologous gene coding sequence is directed by the host regulatory elements of the endogenous gene.

3. The method of claim 1 in which the splice acceptor permits functional integration of the heterologous gene coding sequence into an intron sequence.

4. The method of claim 1 further comprising the step of identifying cells expressing the heterologous gene coding sequence.

5. The method of claim 4 wherein the construct also comprises a gene encoding a selectable marker and the method comprises selecting cells that express the selectable marker.

6. A DNA construct for inserting a gene of interest into a mouse cell genome wherein said DNA construct comprises a heterologous gene sequence which lacks a promoter element and which comprises the sequence: 5' X-A-P-B-Q-C-Y 3' wherein: X and Y are substantially homologous with separate sequences of an endogenous gene, and are of sufficient length to undergo homologous recombination with the endogenous gene so as to insert the A-P-B-Q-C elements into the mouse cell's genome; P is an internal ribosome entry site (IRES); Q is a gene of interest; A, B and C are each independently at least one of a linker sequence and a covalent bond; a polyadenylation site is located 3' (downstream) of Q; and a splice acceptor site is located 5' (upstream) of P.

7. The DNA construct of claim 6 in which the splice acceptor permits functional integration of the heterologous gene into an intron sequence.

8. The DNA construct of claim 6 in which the construct also comprises a gene encoding a selectable marker to facilitate selection of mouse cells containing a heterologous gene that has been inserted into an endogenous gene.

9. The method of claim 1 wherein the gene trap vector also comprises a gene encoding antibiotic resistance, and the method comprises selecting cells that express the antibiotic resistance.

10. The DNA construct of claim 6 wherein the construct additionally comprises a gene encoding antibiotic resistance.

11. A DNA construct for inserting a heterologous gene sequence into a target gene in the genome of a eukaryotic cell, wherein said DNA construct comprises the heterologous gene sequence which comprises the sequence: 5' X-A-P-B-Q-C-Y 3' wherein: X and Y are substantially homologous with separate sequences of the endogenous gene, and are of sufficient length to undergo homologous recombination with the endogenous gene so as to insert the A-P-B-Q-C elements into the genome of the host cell; P is an internal ribosome entry site (IRES); Q is a gene of interest; and A, B, and C are each independently at least one of a linker sequence and a covalent bond.

12. The DNA construct of claim 11, wherein the construct also comprises a gene encoding a selectable marker.

Details for Patent 7,005,299

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2013-04-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2013-04-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2013-04-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.